fbpx
Subscribe
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Archive

Clinical trial reveals new treatment option for COVID-19

Written by | 16 Mar 2022

A clinical trial conducted by researchers from RCSI University of Medicine and Health Sciences and Beaumont Hospital Dublin has indicated an effective treatment for critically ill COVID-19 patients…. read more.

Women with irregular periods may be at risk for liver disease

Written by | 6 Mar 2022

Women with long or irregular periods are known to have a higher risk of type 2 diabetes and heart disease, but researchers found these women may also be… read more.

Researchers develop optical biopsy system that detects liver cancer

Written by | 20 Jan 2022

New instrument could aid diagnosis by helping surgeons pinpoint the best place for a biopsy. Researchers have developed an optical biopsy system that can distinguish between cancerous and… read more.

MHRA approves Bylvay for progressive familial intrahepatic cholestasis – Albireo Pharma

Written by | 18 Jan 2022

Albireo Pharma announced that the UK Medicines and Healthcare Products Regulatory Agency (MHRA) has granted marketing authorization for Bylvay (odevixibat) for the treatment of all types of progressive… read more.

Study introduces new strategy to treat advanced liver cancer

Written by | 19 Nov 2021

Advanced liver cancer, or hepatocellular carcinoma (HCC), currently has limited treatment options and poor prognosis • A recent study introduces a new approach to treat advanced HCC by… read more.

Coffee Consumption Is Associated With Lower Liver Stiffness

Written by | 3 Nov 2021

High coffee consumption was associated with a lower risk for increased liver stiffness (a proxy for fibrosis) but not with steatosis, according to researchers at the University of… read more.

Phase III KEYNOTE-394 trial of Keytruda meets primary endpoint in hepatocellular carcinoma – Merck Inc

Written by | 6 Oct 2021

Merck Inc announced that the Phase III KEYNOTE-394 trial investigating Keytruda (pembrolizumab), Merck’s anti-PD-1 therapy, in Asian patients with advanced hepatocellular carcinoma (HCC) previously treated with sorafenib met… read more.

Antibody-targeted immunotoxins could help treat liver fibrosis

Written by | 22 Jul 2021

University of California – San Diego In mouse models of human disease, immunotoxins targeting the protein mesothelin prevent liver cells from producing collagen, a precursor to fibrosis and… read more.

Drug for common liver condition may be an effective treatment for dementia

Written by | 3 Oct 2020

A drug used to treat cirrhosis of the liver may be an effective treatment for a form of Dementia and motorneuron disease, scientists have discovered. The research, led… read more.

CHMP positive for treatment of plaque psoriasis with Cosentyx in children and adolescents aged 6 to <18 years.- Novartis

Written by | 27 Jun 2020

Novartis, announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion for Cosentyx (secukinumab) for the treatment… read more.

CHMP positive for treatment of plaque psoriasis with Cosentyx in children and adolescents aged 6 to <18 years.- Novartis

Written by | 27 Jun 2020

Novartis, announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion for Cosentyx (secukinumab) for the treatment… read more.

CHMP positive for treatment of plaque psoriasis with Cosentyx in children and adolescents aged 6 to <18 years.- Novartis

Written by | 27 Jun 2020

Novartis, announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion for Cosentyx (secukinumab) for the treatment… read more.

Newsletter Icon

Subscribe for our mailing list

If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.

Subscribe

You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.